Posted by Michael Wonder on 01 Dec 2016
CADTH publishes initial recommendation for Venclexta (venetoclax)
1 December 2016 - The outcome relates to the use of venetoclax for the treatment of patients with chronic lymphocytic leukaemia who have received at least one prior therapy and have a 17p deletion.
The pERC has not recommended the use of venetoclax in this patient population because it was not able to conclude it is associated with a net clinical benefit.
